Pfizer: Earnings Meet Pressure (Rating Upgrade)

Group 1 - Pfizer's stock has underperformed compared to the broader market since the previous analysis, but total return since mid-May has been positive, indicating that the bearish thesis did not develop as expected [1] - The company is facing a patent cliff, which could impact its future performance [1] Group 2 - The author has a background in IT and has been managing a family portfolio for seven years, gaining confidence in investment decisions through fundamental analysis [1] - The insights shared aim to be accessible for investors of all experience levels, focusing on diverse sectors and uncovering promising prospects [1]